The Journal of Allergy and Clinical Immunology
Volume 123, Issue 6 , Pages 1328-1334.e1 , June 2009

Body mass index and phenotype in subjects with mild-to-moderate persistent asthma

  • E. Rand Sutherland, MD, MPH

      Affiliations

    • National Jewish Health, Denver, Colo
    • University of Colorado, Denver, Colo
    • Corresponding Author InformationReprint requests: E. Rand Sutherland, MD, MPH, National Jewish Health, 1400 Jackson St, J-201, Denver, CO 80206.
    • ,
  • Erik B. Lehman, MS

      Affiliations

    • Department of Health Evaluation Sciences, Pennsylvania State University, Hershey, Pa
    • ,
  • Mihaela Teodorescu, MD, MS

      Affiliations

    • Section of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Wisconsin Sleep Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wis
    • Medical Service and The Sleep Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wis
    • ,
  • Michael E. Wechsler, MD, MMSc

      Affiliations

    • Brigham and Women's Hospital, Boston, Mass
    • Harvard Medical School, Boston, Mass
    • ,
  • National Heart, Lung, and Blood Institute's Asthma Clinical Research Network

      Affiliations

    • A list of participating Asthma Clinical Research Network investigators is available in Appendix E1 in this article's Online Repository at www.jacionline.org.

Received 9 February 2009 ,Revised 19 March 2009 ,Accepted 1 April 2009.

References 

  1. Sin DD, Sutherland ER. Obesity and the lung: 4. Obesity and asthma. Thorax. 2008;63:1018–1023
  2. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175:661–666
  3. Camargo CA, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med. 1999;159:2582–2588
  4. Ford ES, Mannino DM, Redd SC, Mokdad AH, Mott JA. Body mass index and asthma incidence among USA adults. Eur Respir J. 2004;24:740–744
  5. Nystad W, Meyer HE, Nafstad P, Tverdal A, Engeland A. Body mass index in relation to adult asthma among 135,000 Norwegian men and women. Am J Epidemiol. 2004;160:969–976
  6. Romieu I, Avenel V, Leynaert B, Kauffmann F, Clavel-Chapelon F. Body mass index, change in body silhouette, and risk of asthma in the E3N cohort study. Am J Epidemiol. 2003;158:165–174
  7. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32–39
  8. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101:2240–2247
  9. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27:495–503
  10. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DYM. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682–687
  11. Eneli IU, Skybo T, Camargo CA. Weight loss and asthma: a systematic review. Thorax. 2008;63:671–676
  12. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000;320:827–832
  13. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med. 2004;169:963–968
  14. Lessard A, Turcotte H, Cormier Y, Boulet LP. Obesity and asthma: a specific phenotype?. Chest. 2008;134:317–323
  15. Shore SA. Obesity and asthma: lessons from animal models. J Appl Physiol. 2007;102:516–528
  16. Beuther DA, Sutherland ER. Obesity and pulmonary function testing. J Allergy Clin Immunol. 2005;115:1100–1101
  17. Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J. 2006;13:203–210
  18. Sutherland TJ, Cowan JO, Young S, Goulding A, Grant AM, Williamson A, et al. The association between obesity and asthma: interactions between systemic and airway inflammation. Am J Respir Crit Care Med. 2008;178:469–475
  19. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol. 2005;115:897–909
  20. Martin RJ, Kephart DK, Dyer AM, Fahy J, Kraft M. Quality control within the Asthma Clinical Research Network. Control Clin Trials. 2001;22(suppl):207S–221S
  21. Denlinger LC, Sorkness CA, Chinchilli VM, Lemanske RF. Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network. J Allergy Clin Immunol. 2007;119:3–11
  22. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda: US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program; 2007;
  23. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996;335:841–847
  24. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  25. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377–1383
  26. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352:1519–1528
  27. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410–418
  28. Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119:73–80
  29. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285:2594–2603
  30. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2007;175:228–234
  31. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175:783–790
  32. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583–2593
  33. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14:32–38
  34. Tantisira KG, Litonjua AA, Weiss ST, Fuhlbrigge AL. Association of body mass with pulmonary function in the Childhood Asthma Management Program (CAMP). Thorax. 2003;58:1036–1041
  35. Wenzel SE, Busse WW. Severe asthma: Lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:14–21
  36. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000;162:2341–2351
  37. Flemons WW. Clinical practice. Obstructive sleep apnea. N Engl J Med. 2002;347:498–504
  38. Jacobson BC, Somers SC, Fuchs CS, Kelly CP. Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340–2348
  39. Chan CS, Woolcock AJ, Sullivan CE. Nocturnal asthma: role of snoring and obstructive sleep apnea. Am Rev Respir Dis. 1988;137:1502–1504
  40. Ciftci TU, Ciftci B, Guven SF, Kokturk O, Turktas H. Effect of nasal continuous positive airway pressure in uncontrolled nocturnal asthmatic patients with obstructive sleep apnea syndrome. Respir Med. 2005;99:529–534
  41. Guilleminault C, Quera-Salva MA, Powell N, Riley R, Romaker A, Partinen M, et al. Nocturnal asthma: snoring, small pharynx and nasal CPAP. Eur Respir J. 1988;1:902–907

 Supported by National Institutes of Health grants (U10) HL51831, HL51845, HL51823, HL51843, HL56443, HL51834, HL51810, HL74227, HL74231, HL074204, HL74212, HL74073, HL074206, HL074208, HL74225, and HL74218.

 Disclosure of potential conflict of interest: E. R. Sutherland is on advisory boards for GlaxoSmithKline, and Dey; is a Data and Safety Monitoring Board member for Schering-Plough; and received grant support from the National Institutes of Health, Novartis and Dey. M. Teodorescu received grant support from the University of Wisconsin School of Medicine and Public Health. M. E. Wechsler is a consultant for AstraZeneca, Schering-Plough, Novartis, GlaxoSmithKline, Merck, and Genentech; is on the advisory board for AstraZeneca, Schering-Plough, Novartis, GlaxoSmithKline, Merck, and Genentech; is on the speakers' bureau for AstraZeneca, Novartis, GlaxoSmithKline, Merck, and Genentech; and receives grant support from Asthmatx, GlaxoSmithKline, and the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00557-0

doi: 10.1016/j.jaci.2009.04.005

The Journal of Allergy and Clinical Immunology
Volume 123, Issue 6 , Pages 1328-1334.e1 , June 2009

Article Tools